What was recalled
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall involving a specific batch of prescription medication manufactured by American Regent, Inc. This action, announced on July 24, 2026, targets niCARdipine Hydrochloride Injection, USP. To understand exactly what is affected, it is helpful to look at the precise specifications of the product in question. The recall focuses on a dosage strength of 25 mg per 10 mL (which equates to 2.5 mg/mL). This medication is packaged in two distinct formats: first, as individual 10 mL Single Dose Vials, and second, as multi-packs containing ten 10 mL Single Dose Vials.
Identifying the correct product requires checking the National Drug Code (NDC) numbers printed on the packaging. The specific NDCs subject to this recall are 72572-470-01 for the single-dose vials and 72572-470-10 for the ten-vial packs. These items are designated as prescription-only (Rx Only) medications, meaning they are not available over the counter and are typically dispensed in hospital or clinical settings rather than through standard retail pharmacies for home use. The manufacturing details listed on the labels indicate that while American Regent, Inc., located in New Albany, Ohio, is the brand owner, the product was manufactured by Civica, Inc., in Lehi, Utah.
The scope of this recall is defined strictly by lot number and expiration date to ensure that only potentially compromised units are removed from the supply chain. The affected inventory carries Lot Number 25295N0C0. This specific lot has an expiration date of April 30, 2027. It is crucial to note that niCARdipine Hydrochloride Injection is a sterile product intended for intravenous use, often used in critical care settings to manage blood pressure. Because of its nature, the distribution pattern for this drug was nationwide within the United States. This means that healthcare facilities across all states could potentially have received these vials, although the FDA record specifically notes New York as a jurisdiction involved in the reporting or distribution chain. If you are a patient or a medical professional who has recently handled these vials, verifying the lot number against the one listed above is the only way to confirm if your specific units are part of this recall.
The hazard, explained
When the U.S. Food and Drug Administration (FDA) issues a Class II recall for niCARdipine Hydrochloride Injection, USP, they are addressing a serious but potentially manageable manufacturing defect: the presence of particulate matter within the sterile solution. In plain terms, this means that tiny, unwanted solid objects have ended up inside the liquid medication where they do not belong. According to the official recall notice from American Regent, Inc., these foreign contaminants have been identified as hair, glass, and/or paraformaldehyde. To understand why this is dangerous, it helps to look at how intravenous (IV) medications are supposed to work and what happens when that process is compromised.
NiCARdipine is a calcium channel blocker used to manage high blood pressure, typically administered directly into a vein in a hospital or clinical setting. When injected, the liquid must be perfectly clear and free of any solid debris. The human body’s vascular system acts as a delicate filter network. Small blood vessels can become blocked if foreign particles enter the bloodstream. This condition is known as embolization. If glass shards are present, they are rigid and sharp; they do not dissolve or break down safely inside the body. Instead, they can physically obstruct capillaries, potentially causing tissue damage, inflammation, or localized ischemia (lack of blood flow) in the affected area. Hair fibers, while seemingly less dangerous than glass, are still foreign biological material that can trigger immune responses or serve as a nidus for clot formation.
The presence of paraformaldehyde adds another layer of chemical risk. Paraformaldehyde is a polymer of formaldehyde, a substance known to be irritating and toxic in certain concentrations. If this contaminant is present in the injection vial, it suggests a failure in the cleaning or sterilization process during manufacturing. When introduced into the bloodstream, paraformaldehyde can cause severe local irritation at the injection site, leading to phlebitis (inflammation of the vein), pain, and potentially systemic toxicity if absorbed in significant amounts. Unlike glass or hair, which are physical obstructions, paraformaldehyde is a chemical hazard that can disrupt cellular function.
The combination of these three types of contaminants—physical debris and chemical residue—creates a complex safety profile. The immediate concern is not just the blockage of blood flow, but also the potential for an inflammatory reaction to the foreign materials. For patients receiving niCARdipine, who are often critically ill or under close medical supervision, this introduces an unnecessary and preventable variable into their treatment plan. The integrity of every single dose in the affected lot (25295N0C0) is compromised because the contamination could be unevenly distributed within the vial. This is why the FDA classifies this as a Class II recall: while it may not cause serious adverse health effects or death in every case, it poses a temporary or medically significant risk that requires immediate correction to ensure patient safety.
Who is most at risk
When a Class II recall involves niCARdipine Hydrochloride Injection, the primary group at risk is not the general public, but rather patients currently undergoing intensive care treatment who require precise control over their blood pressure. This medication is typically administered in hospital settings, such as emergency rooms or intensive care units, to treat severe hypertension. Therefore, the individuals most vulnerable to this specific recall are those with acute cardiovascular conditions who are dependent on intravenous medications to stabilize their health. Because niCARdipine is a potent calcium channel blocker used for rapid blood pressure reduction, patients receiving it are often in critical condition themselves. The introduction of particulate matter—specifically hair, glass fragments, or paraformaldehyde—into the infusion line poses an immediate and severe threat to these already fragile bodies.
The danger here is twofold: mechanical blockage and chemical toxicity. For patients with compromised circulatory systems, any foreign object introduced directly into a vein can lead to micro-emboli, which are small clots or debris that travel through the bloodstream. If these particles lodge in smaller blood vessels, they can cause tissue damage, inflammation, or even organ failure depending on where the blockage occurs. This is particularly concerning for elderly patients, whose blood vessels may already be more fragile or narrowed due to age-related conditions like atherosclerosis. For these individuals, the margin for error in medical treatment is incredibly thin; even a small amount of contamination can trigger a disproportionate adverse reaction compared to a healthier adult.
Additionally, the presence of paraformaldehyde introduces a different layer of risk. Paraformaldehyde is a polymer of formaldehyde, and its presence in an injectable drug suggests potential manufacturing contamination that could lead to systemic toxicity. Patients with pre-existing liver or kidney impairment, who are common among those requiring intensive cardiac care, may have reduced ability to metabolize and eliminate toxins from their bodies. This makes them more susceptible to the harmful effects of any chemical contaminants present in the drug. Furthermore, because the recall affects products distributed nationwide, there is no geographic barrier protecting patients; anyone receiving this specific lot (25295N0C0) at any healthcare facility across the United States faces the same potential risks.
It is also important to note that while the hazard is serious, the risk is largely contained within professional medical environments. Individual consumers are unlikely to encounter this product directly at home, as it is a prescription-only injectable used under strict clinical supervision. However, for those currently hospitalized and receiving niCARdipine Hydrochloride Injection from the affected lots, the stakes are high. Healthcare providers must act quickly to verify the inventory and substitute alternative medications if necessary. Patients and their families should be aware that while the recall is a Class II event—meaning it is not expected to cause serious adverse health consequences or death in most cases—it still requires immediate attention to prevent potential complications. Vigilance from medical staff is the best defense for those at risk.
How to tell if you have the recalled item
If you are a healthcare professional or work in a pharmacy setting, verifying whether your inventory contains the affected product requires careful attention to specific details on the packaging and labeling. This recall involves niCARdipine Hydrochloride Injection, USP, which is manufactured by American Regent, Inc., located in New Albany, Ohio. Because this medication is prescribed for hospital or clinical use rather than sold directly to consumers in retail stores, your verification process will focus on stockrooms, automated dispensing cabinets, and pharmacy shelves.
First, check the primary container labels for the exact product name: niCARdipine Hydrochloride Injection, USP. The concentration is critical to identify correctly; you are looking for a strength of 25 mg/10mL, which is equivalent to 2.5 mg/mL. This medication comes in two specific package configurations that are subject to this recall. You may have the product in either a single-dose vial containing 10 mL of solution or in a carton containing ten 10 mL single-dose vials. If you see packaging that matches these descriptions, proceed to the next verification step.
The most definitive way to confirm if your stock is part of this recall is to examine the National Drug Code (NDC) numbers printed on the label. The recalled items carry one of the following two NDCs: 72572-470-01 for the single vial package, or 72572-470-10 for the ten-vial carton. If your inventory does not list these specific NDC numbers, it is not part of this particular recall action. Additionally, verify the manufacturer information on the label. While American Regent, Inc. is the brand owner and manufacturer, the product was manufactured for Civica, Inc., located in Lehi, Utah. Both names may appear on the labeling, but the NDC and lot number are the primary keys to identification.
Once you have matched the product name, strength, and NDC, you must check the Lot Number. Only items with Lot Number 25295N0C0 are included in this recall. Please note that other lots of the same drug from American Regent or Civica are not affected by this specific action. If your vials bear this exact lot number, do not use them for patient care. The expiration date for this recalled lot is April 30, 2027, but the recall status overrides the expiration date due to the safety hazard. By systematically checking these four identifiers—product name/strength, NDC, manufacturer details, and Lot Number—you can accurately determine if your inventory is involved.
What to do — step by step
If you are a healthcare provider, pharmacist, or facility manager currently holding inventory of the recalled niCARdipine Hydrochloride Injection, USP, your immediate priority is patient safety and strict adherence to federal recall protocols. Because this specific recall involves the presence of particulate matter—identified as hair, glass, and/or paraformaldehyde—the risk is not merely one of ineffectiveness but of direct physical harm upon administration. The FDA has classified this as a Class II recall, which indicates that use of the product may cause temporary or medically reversible serious injury, or the probability of serious injury is remote but still significant. Therefore, you must act with urgency and precision.
- Stop Use Immediately: Remove all units of the recalled niCARdipine Hydrochloride Injection, USP (25 mg/10mL) from clinical use areas, pharmacy shelves, and automated dispensing cabinets. Do not administer any doses from Lot #25295N0C0 to patients under any circumstances. This includes vials that appear visually clear; particulate matter such as hair or glass fragments may be microscopic or obscured by the solution's opacity, making visual inspection unreliable for safety confirmation.
- Quarantine the Product: Physically isolate the recalled stock from non-recalled inventory. Place the vials in a clearly labeled area marked "DO NOT USE" or "RECALLED PRODUCT." This prevents accidental administration by staff who may not have received the recall notice yet. Proper segregation is critical to maintaining chain of custody and ensuring that no contaminated units are inadvertently dispensed during an emergency.
- Contact Your Supplier: Reach out to your pharmaceutical distributor or vendor immediately to report the receipt of the recalled lots. Inform them that you have identified NDC 72572-470-01 (10 mL Single Dose Vial) and/or NDC 72572-470-10 (10x10 mL Single Dose Vials) manufactured by American Regent, Inc. for Civica, Inc., with expiration date 04/30/2027. Request specific instructions on how to return the product or if they will arrange for pickup.
- Follow Official Disposition Instructions: In this instance, the official recall notice does not explicitly state the remedy, such as whether you should return the product for a refund or simply destroy it under supervision. Because the remedy is not stated in the available data, you must contact American Regent, Inc., directly at their New Albany, OH facility, or your specific distributor to determine the correct disposal method. Do not discard these vials in regular medical waste until you have confirmed the proper protocol with the manufacturer or regulatory guidance, as improper handling of pharmaceutical recalls can lead to further compliance issues.
- Notify Affected Patients: If any doses from this lot were administered to patients prior to the recall notice, your clinical team must assess those patients for any adverse events related to particulate ingestion or injection. Document any incidents thoroughly and report them to the FDA’s MedWatch program. Patient safety is the paramount concern, and transparency in follow-up care is essential.
Remember, while the general steps for handling drug recalls are standard, the specific remedy for this recall is not stated in the current facts provided. Always verify your next move directly with American Regent, Inc., or the FDA to ensure you are meeting all legal and safety obligations.
Your refund, repair, or replacement options
When a recall is issued for a pharmaceutical product, the primary concern is always safety, but the logistical question of what happens next is equally important for patients and healthcare providers. In this specific instance involving American Regent, Inc., the situation is somewhat unusual because the official FDA recall facts do not explicitly state the remedy. This means there is no confirmed information regarding refunds, repairs, or replacements in the current public record. While this might feel frustrating or confusing, it is crucial to understand why this gap exists and what it implies for your next steps. First, it is helpful to clarify that pharmaceutical products like niCARdipine Hydrochloride Injection are generally not "repairs" items. Unlike a defective toaster or a malfunctioning car part, a drug cannot be fixed or refilled once it has left the manufacturing line. Therefore, the only realistic options for resolving this issue would be a full refund of the purchase price or a replacement with a non-recalled batch from a different lot number. However, because the recall notice does not specify which of these actions will be taken, you cannot assume one is guaranteed. The absence of stated remedy details suggests that the distribution may have been limited to specific hospital systems or pharmacies that already have direct contractual lines of communication with American Regent and Civica, Inc., rather than a mass consumer return process. If you are a patient who has recently received this medication, your first step should not be to contact the manufacturer directly for a refund, as they likely do not handle individual patient reimbursements for hospital-administered drugs. Instead, you must speak with the healthcare provider or pharmacist who dispensed or administered the injection. They are the ones who hold the transaction records and the direct channel to the supplier. For those in New York or nationwide who might have purchased this product through a retail pharmacy, that pharmacist is your primary point of contact. They can verify if they still have stock of the recalled lot (NDC 72572-470-01 or NDC 72572-470-10) and will guide you on how to return it. It is also important to note that because this is a Class II recall, the risk of serious adverse health consequences is theoretically possible but unlikely compared to a Class I recall. This classification often means that the remedy process may be handled quietly through healthcare networks rather than via public refunds. Do not attempt to mail the product back yourself unless explicitly instructed by your pharmacy or doctor. The presence of particulate matter, such as hair or glass, makes handling these vials hazardous. Proper disposal is required, and your healthcare provider will coordinate with American Regent, Inc., based in New Albany, OH, to arrange for safe return or destruction of the contaminated inventory. Until further details are released by the FDA, your best course of action is to rely on the professional guidance of your medical team, who can ensure you receive appropriate care without financial penalty from the defective product.What can happen if you ignore it
When a pharmaceutical product is recalled due to the presence of foreign particulate matter—such as hair, glass, or paraformaldehyde—the stakes are significantly higher than with many other types of consumer product recalls. This is because niCARdipine Hydrochloride Injection is not a topical cream you might wash off or an over-the-counter supplement you can simply stop taking without consequence. It is a sterile medication administered via injection, typically into the bloodstream or muscle tissue, to manage critical health conditions such as high blood pressure. Ignoring this recall means continuing to introduce these contaminants directly into your body’s internal systems, bypassing the natural protective barriers of the skin.
The most immediate and severe risk involves physical trauma from solid particles. If glass shards or hair are present in the vial, they do not dissolve when injected. Instead, they travel with the flow of blood to smaller vessels throughout the body. In the lungs, these particles can cause pulmonary emboli, blocking blood flow and potentially leading to tissue death or severe respiratory distress. In the brain, even microscopic fragments can obstruct tiny capillaries, which may result in strokes, transient ischemic attacks, or permanent neurological damage. The body cannot "filter out" large enough particulates once they have entered the circulatory system; they become foreign bodies that trigger inflammation, clotting, and potential organ failure.
Beyond physical obstruction, there is a profound risk of chemical toxicity and immune reaction. Paraformaldehyde, if present as a contaminant, is a known irritant and toxic compound. When introduced directly into the bloodstream, it can cause severe local tissue necrosis (death) at the injection site and systemic reactions that may include fever, chills, and organ stress. Hair and other organic materials can serve as a nidus for bacterial growth, even if the vial was originally sealed. This dramatically increases the risk of serious infections, including sepsis, which is a life-threatening response to infection that can lead to tissue damage, organ failure, and death. The immune system will mount an aggressive defense against these foreign invaders, potentially causing severe allergic-like reactions or inflammatory syndromes.
Furthermore, using contaminated medication undermines the integrity of your medical treatment. If you are receiving niCARdipine for blood pressure control, the presence of particulates can alter the dosage delivery or cause pain and inflammation that masks other symptoms. This makes it difficult for healthcare providers to assess your true condition. In a clinical setting, this could lead to misdiagnosis or delayed treatment for other underlying issues. The psychological toll of knowing you have been exposed to unknown contaminants should not be underestimated either; the anxiety associated with potential long-term health effects can exacerbate stress-related conditions, which is counterproductive when managing hypertension.
It is crucial to understand that these risks are not theoretical. While the recall notice does not specify exact injury counts, the nature of particulate contamination in injectable drugs is well-documented in medical literature as a cause of serious adverse events. The FDA classifies this as a Class II recall because it is likely to cause temporary or medically significant adverse health consequences. Ignoring the recall means gambling with your vascular health, immune system integrity, and overall safety. The potential for irreversible harm far outweighs the inconvenience of returning the product. Please contact your healthcare provider immediately if you have used any of the affected lots to discuss appropriate monitoring and next steps.
Staying safe: broader tips
While this specific recall highlights a serious manufacturing defect involving particulate matter in an injectable medication, it serves as a powerful reminder of why vigilance is essential when handling any pharmaceutical product. The presence of foreign objects like hair, glass, or chemical residues in sterile injections is a failure of the production line that no consumer can prevent directly. However, you can protect yourself by becoming an active participant in the safety chain between the manufacturer and your body. This starts with understanding how to verify the integrity of the products you receive, especially those dispensed through hospitals or specialized pharmacies where large-scale distribution increases the complexity of tracking.
One of the most effective ways to stay safe is to maintain a personal record of the medications you use, particularly those administered in clinical settings. Keep a simple log that includes the drug name, the manufacturer, and the lot number found on the packaging. If you are a caregiver or manage medication for someone with complex health needs, ask your healthcare provider or pharmacist to confirm the lot numbers during dispensing. This creates a paper trail that makes it much easier to cross-reference with FDA recall notices if an issue arises. When you see a recall notice, having this information on hand allows you to act immediately rather than scrambling to find details under stress.
Beyond tracking specific lots, it is crucial to understand the difference between Class II and Class I recalls. A Class II recall, like the one involving American Regent’s niCARdipine Hydrochloride, indicates a product that might cause temporary or medically reversible health problems. While this sounds less severe than a Class I recall, it still demands immediate attention because the source of contamination—such as paraformaldehyde or glass shards—can lead to embolisms, infections, or inflammatory responses if injected. Always treat any notification from the FDA or your pharmacy with urgency. Do not assume that because a drug is widely used or has been on the market for years that it is immune to manufacturing errors.
Finally, stay connected to official safety channels. Subscribe to email alerts from the U.S. Food and Drug Administration (FDA) and check their website regularly. Many people overlook these resources until they hear about a recall in the news, by which time it may be too late to check their own records. By making it a habit to monitor these updates, you ensure that you are not just reacting to crises but proactively safeguarding your health. Remember that safety is a shared responsibility; while manufacturers must maintain sterile environments, consumers must remain informed and ready to act when those standards are compromised.